Faecal calprotectin is highly effective to detect endoscopic ulcerations in Crohn's disease regardless of disease location

被引：0
|
作者：
Buisson, A. [1 ,2 ,3 ]
Mak, W. Y. [4 ,5 ]
Andersen, M. J., Jr. [5 ]
Lei, D. [5 ]
Pekow, J. [5 ]
Cohen, R. D. [5 ]
Pereira, B. [6 ]
Rubin, D. T. [5 ]
机构：
[1] Univ Hosp Estaing, Gastroenterol Dept, Clermont Ferrand, France
[2] Univ Auvergne, INSERM, UMR 1071, Clermont Ferrand, France
[3] USC INRA 2018, Microbes Intestine Inflammat & Susceptibil Host, Clermont Ferrand, France
[4] Queen Elizabeth Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China
[5] Univ Chicago Med, Inflammatory Bowel Dis Ctr, Chicago, IL USA
[6] Univ Hosp, Biostat Unit, DRCI, Clermont Ferrand, France
来源：
JOURNAL OF CROHNS & COLITIS | 2018年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P306
引用
收藏
页码：S255 / S255
页数：1
相关论文
共 50 条
  • [21] Modelling of the relationship between ustekinumab exposure, faecal calprotectin and endoscopic outcomes in patients with Crohn's disease
    Wang, Z.
    Verstockt, B.
    Vermeire, S.
    Sabino, J.
    Ferrante, M.
    Declerck, P.
    Dreesen, E.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S335 - S336
  • [22] Modelling of the relationship between infliximab exposure, faecal calprotectin, and endoscopic remission in patients with Crohn's disease
    Dreesen, E.
    Berends, S.
    Laharie, D.
    D'Haens, G.
    Vermeire, S.
    Gils, A.
    Mathot, R.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S052 - S053
  • [23] Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn's disease
    Dreesen, Erwin
    Berends, Sophie
    Laharie, David
    D'Haens, Geert
    Vermeire, Severine
    Gils, Ann
    Mathot, Ron
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (01) : 106 - 118
  • [24] Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment
    Sipponen, Taina
    Bjorkesten, Clas-Goran A. F.
    Farkkila, Martti
    Nuutinen, Hannu
    Savilahti, Erkki
    Kolho, Kaija-Leena
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2010, 45 (03) : 325 - 331
  • [25] Are lower levels of faecal calprotectin reassuring in Crohn's Disease patients?
    Monteiro, S.
    de Castro, F. Dias
    Leite, S.
    Moreira, M. J.
    Cotter, J.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S198 - S199
  • [26] Diffusion-weighted magnetic resonance imaging is effective to detect ileocolonic ulcerations in Crohn's disease
    Buisson, A.
    Hordonneau, C.
    Goutte, M.
    Boyer, L.
    Pereira, B.
    Bommelaer, G.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (04) : 452 - 460
  • [27] Faecal calprotectin is the biomarker that best distinguishes remission from different degrees of endoscopic activity in Crohn's disease
    Cancela e Penna, Francisco Guilherme
    Rosa, Rodrigo Macedo
    Sales da Cunha, Pedro Ferrari
    Silva de Souza, Stella Cristina
    de Abreu Ferrari, Maria de Lourdes
    BMC GASTROENTEROLOGY, 2020, 20 (01)
  • [28] Faecal calprotectin is the biomarker that best distinguishes remission from different degrees of endoscopic activity in Crohn’s disease
    Francisco Guilherme Cancela e Penna
    Rodrigo Macedo Rosa
    Pedro Ferrari Sales da Cunha
    Stella Cristina Silva de Souza
    Maria de Lourdes de Abreu Ferrari
    BMC Gastroenterology, 20
  • [29] Utility of faecal calprotectin to assess Crohn's disease activity in patients with an ileostomy
    Rowan, C. R.
    Alzubi, S.
    Healy, M.
    Cullen, G.
    Mulcahy, H.
    Sheridan, J.
    Doherty, G. A.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S268 - S268
  • [30] A Prospective Evaluation of the Predictive Value of Faecal Calprotectin in Quiescent Crohn's Disease
    Smith, Lyn A.
    Naismith, Graham
    Barry, Sarah
    Rankin, Karen
    Munro, Joanna I.
    Laird, Susan
    Winter, Jack W.
    Morris, Allan J.
    Gaya, Daniel R.
    GASTROENTEROLOGY, 2013, 144 (05) : S765 - S765
12345